September 9, 2022 06:39 AM EDTUpdated September 12, 10:56 AM
Peer Review

Ho­mol­o­gy sails with same cap­tains in dif­fer­ent seats; Ex-Har­poon chief weath­ers the Storm at UK biotech

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Kyle LaHucik

Senior Reporter

Af­ter a mul­ti-year run as co-work­ers at Shire Phar­ma­ceu­ti­cals, Arthur Tzian­a­bos and Al­bert Sey­mour got the band back to­geth­er in 2016 as two of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times